Advertisement
"Doctors, commercial reference labs, and pharma companies send theirsamples to us from around the world for testing because of our uniqueexpertise in allergy and immunology. We have a scientific team dedicated fulltime to new assay development so we can offer customers the latest,most-comprehensive range of molecular and cellular immunology assaysavailable," said Dr. Halsey. "Over the past several years, IBT has enjoyeddouble-digit growth in all segments of the business. Unlike many referencelabs that perform testing exclusively for either clinical diagnostics orpharmaceutical customers, we do both, and each part of the business supportsand informs the other. I am delighted that Maureen has joined us. Withday-to-day operations and implementation of our ambitious growth strategy inher capable hands, I will be able to devote my time to expanding our researchand testing services and developing strategic partnerships to further thescientific mission of the company."
Advertisement
Previously, Ms. Loftus served in senior leadership positions withcompanies across a variety of industries, most recently as president of TheBode Technology Group, Inc, one of the nation's leading providers of forensicDNA analysis. Prior to that, Ms. Loftus was chief operating officer ofIdentico Systems, a pioneer in biometric-enabled identity-verificationsystems. In addition, she has more than 10 years experience as a managementconsultant to Fortune 500 companies on strategic, operational, andorganizational issues. Ms. Loftus earned her undergraduate degree in businessadministration at Washington University's John M. Olin School of Business inSt. Louis, and holds a master's degree in management from Kellogg GraduateSchool of Business at Northwestern University.
"This is an exciting time for IBT Labs, and I am thrilled to be part ofit," said Ms. Loftus. "The immunology and allergy arena is becoming anincreasingly important niche market for testing and research, particularlywith the broader development of protein-based therapeutics. These drugs workby triggering the body's immune system. IBT's assays can be used to determinethe subset of the population that will benefit from the therapeutic. Equallyimportant -- our assays can identify whether a person is likely to have apotentially fatal allergic response -- before the doctor prescribes the drug.The FDA now requires immunotoxicology testing for all drug development. IBT'sexpertise in immunology and allergy, and its strong track record of new assaydevelopment aligns it strategically with the growing demands -- from biomarkerand drug-development research to clinical trials and diagnostic testing."
Commenting on Ms. Loftus' appointment, IBT Lab's Executive Chairman,Laurence McCarthy, Ph.D., said "Maureen is an experienced leader and hasmanaged high-growth organizations over the last 12 years. Her leadership willbe essential as the company looks to capitalize on growing demand for itsdiagnostic-testing services, assay development, and outsourced clinical-trialtesting."
About IBT Laboratories
A clinical diagnostic and research laboratory specializing in immunologyand allergy testing, IBT tests patient samples for physicians, hospitals, andcommercial reference labs from around the globe. IBT also provides biomarkerand immunotoxicology testing services to pharmaceutical an
